What is the recommended dupilumab dosing schedule for patients ≥12 years (or ≥40 kg) and for children 6‑11 years based on weight?

Dupilumab Dosing for Atopic Dermatitis

For patients ≥12 years or ≥40 kg with atopic dermatitis, administer dupilumab 600 mg loading dose (two 300 mg injections) followed by 300 mg every 2 weeks; for children 6-11 years, use weight-tiered dosing with loading doses followed by either 300 mg every 4 weeks (15 to <30 kg) or 200 mg every 2 weeks (30 to <60 kg). 1

Dosing for Patients ≥12 Years and ≥40 kg

Adults and adolescents ≥12 years:

• Initial loading dose: 600 mg (administered as two 300 mg subcutaneous injections) 1
• Maintenance dose: 300 mg subcutaneously every 2 weeks (Q2W) 1

This regimen applies to all patients in this age group regardless of weight, as the FDA-approved dosing for atopic dermatitis in patients ≥60 kg is standardized at this level 1.

Weight-Tiered Dosing for Children 6-11 Years

For pediatric patients 6-11 years, dosing is strictly weight-based with loading doses: 1

Children 15 to <30 kg:

• Loading dose: 600 mg (two 300 mg injections) 1
• Maintenance: 300 mg every 4 weeks (Q4W) 1

Children 30 to <60 kg:

• Loading dose: 400 mg (two 200 mg injections) 1
• Maintenance: 200 mg every 2 weeks (Q2W) 1

Children ≥60 kg:

• Loading dose: 600 mg (two 300 mg injections) 1
• Maintenance: 300 mg every 2 weeks (Q2W) 1

Critical Dosing Considerations

The weight-tiered approach in children 6-11 years is based on pharmacokinetic modeling demonstrating that these regimens achieve comparable drug exposures to the adult 300 mg Q2W regimen, which is essential for optimal efficacy. 2 Real-world data confirm that response to therapy is weight-dependent, with optimal doses being 300 mg Q4W for children <30 kg and 200 mg Q2W for children ≥30 kg. 3

Loading doses are mandatory in the pediatric population to achieve therapeutic drug levels more rapidly. 1 The FDA labeling explicitly includes loading doses for all weight categories in children 6-11 years, unlike some other indications where loading doses may be optional. 1

Administration Details

• Route: Subcutaneous injection only 1
• Concomitant therapy: Dupilumab can be used with or without topical corticosteroids in atopic dermatitis 1
• Expected response timeline: Assess treatment response at 16 weeks using validated measures 4

Safety Monitoring Requirements

Monitor for ocular adverse events, particularly conjunctivitis, which occurs in approximately 25% of patients, typically within the first 4 months of treatment. 4, 5 Advise patients to report new onset or worsening eye symptoms immediately. 1

Common adverse events include: 4

• Injection-site reactions
• Conjunctivitis
• Oral herpes (manageable events)

Preservative-free ocular lubricants should be readily available for patients who develop ocular symptoms. 4